{"id":"levodopa-carbidopa-ld-cd","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Nausea"},{"rate":"20-40","effect":"Dyskinesia"},{"rate":"10-20","effect":"Orthostatic hypotension"},{"rate":"10-20","effect":"Dizziness"},{"rate":"5-15","effect":"Hallucinations"},{"rate":"5-10","effect":"Confusion"},{"rate":"variable with disease progression","effect":"On-off fluctuations"}]},"_chembl":{"chemblId":"CHEMBL1200748","moleculeType":"Small molecule","molecularWeight":"244.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa (L-DOPA) is a precursor to dopamine that can cross the blood-brain barrier, unlike dopamine itself. Carbidopa is a peripheral decarboxylase inhibitor that prevents levodopa from being converted to dopamine outside the brain, thereby increasing the amount of levodopa available for conversion to dopamine in the CNS. This combination restores dopaminergic neurotransmission in Parkinson's disease patients who have progressive loss of dopamine-producing neurons.","oneSentence":"Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion in the periphery, allowing more levodopa to reach the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:50.495Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Restless legs syndrome (off-label use)"}]},"trialDetails":[{"nctId":"NCT05708274","phase":"PHASE1","title":"Pharmacological Agents for Chronic Spinal Cord Injury (SCI)","status":"COMPLETED","sponsor":"Bronx VA Medical Center","startDate":"2023-01-20","conditions":"Spinal Cord Injuries","enrollment":25},{"nctId":"NCT06765668","phase":"PHASE4","title":"A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease","status":"RECRUITING","sponsor":"Impax Laboratories, LLC","startDate":"2025-02-12","conditions":"Parkinson Disease","enrollment":220},{"nctId":"NCT04750226","phase":"PHASE3","title":"Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-02-18","conditions":"Parkinson's Disease (PD)","enrollment":118},{"nctId":"NCT04379050","phase":"PHASE3","title":"Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-06-08","conditions":"Parkinson's Disease (PD)","enrollment":130},{"nctId":"NCT05471609","phase":"EARLY_PHASE1","title":"Sustained Release Oral Formulation for Treatment of Parkinson's Disease","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2025-06-12","conditions":"Healthy Volunteers","enrollment":6},{"nctId":"NCT02726386","phase":"PHASE2","title":"A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2016-05-04","conditions":"Parkinson's Disease","enrollment":214},{"nctId":"NCT04006210","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2019-09-30","conditions":"Parkinson's Disease","enrollment":381},{"nctId":"NCT02096601","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2014-08-11","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT02763137","phase":"PHASE2","title":"Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients","status":"COMPLETED","sponsor":"IRCCS San Raffaele Roma","startDate":"2014-07-30","conditions":"Parkinson Disease","enrollment":18},{"nctId":"NCT02604914","phase":"PHASE1","title":"A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-05-29","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT02577523","phase":"PHASE2","title":"A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-12-29","conditions":"Parkinson's Disease","enrollment":38},{"nctId":"NCT05094050","phase":"PHASE1","title":"Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-01-18","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT04380142","phase":"PHASE3","title":"Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-10-19","conditions":"Parkinson's Disease (PD)","enrollment":174},{"nctId":"NCT04778176","phase":"PHASE2","title":"Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"SynAgile Corporation","startDate":"2021-06-16","conditions":"Parkinson's Disease","enrollment":17},{"nctId":"NCT03007888","phase":"PHASE2","title":"A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2016-11-14","conditions":"Advanced Parkinson's Disease","enrollment":28},{"nctId":"NCT00974974","phase":"PHASE3","title":"A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2009-09","conditions":"Parkinson's Disease","enrollment":471},{"nctId":"NCT04236921","phase":"PHASE1","title":"Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)","status":"COMPLETED","sponsor":"Riverside Pharmacueticals Corporation","startDate":"2019-07-15","conditions":"Other","enrollment":57},{"nctId":"NCT00869791","phase":"PHASE2","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2008-11","conditions":"Parkinson's Disease","enrollment":27},{"nctId":"NCT01096186","phase":"PHASE3","title":"An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2010-03","conditions":"Parkinson's Disease","enrollment":617},{"nctId":"NCT01411137","phase":"PHASE3","title":"Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2011-08","conditions":"Parkinson's Disease","enrollment":43},{"nctId":"NCT02271503","phase":"PHASE2","title":"A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2015-11","conditions":"Parkinson's Disease","enrollment":26},{"nctId":"NCT00880620","phase":"PHASE3","title":"A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2009-04","conditions":"Parkinson's Disease","enrollment":381},{"nctId":"NCT00279825","phase":"PHASE2","title":"Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2006-01","conditions":"Idiopathic Parkinson's Disease","enrollment":16},{"nctId":"NCT00253084","phase":"PHASE2","title":"Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2005-11","conditions":"Parkinson's Disease","enrollment":12},{"nctId":"NCT00239564","phase":"PHASE1, PHASE2","title":"Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2005-10","conditions":"Idiopathic Parkinson's Disease","enrollment":12},{"nctId":"NCT02605434","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients","status":"UNKNOWN","sponsor":"Intec Pharma Ltd.","startDate":"2016-03","conditions":"Parkinson's Disease","enrollment":420},{"nctId":"NCT03887884","phase":"PHASE1","title":"Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2019-03-05","conditions":"Parkinson's Disease","enrollment":23},{"nctId":"NCT02615873","phase":"PHASE3","title":"A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004","status":"UNKNOWN","sponsor":"Intec Pharma Ltd.","startDate":"2016-07","conditions":"Parkinson's Disease","enrollment":460},{"nctId":"NCT03576638","phase":"PHASE2","title":"Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients","status":"UNKNOWN","sponsor":"Intec Pharma Ltd.","startDate":"2018-07","conditions":"Parkinson Disease","enrollment":12},{"nctId":"NCT01617135","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and \"Off\" Episodes","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2012-05","conditions":"Idiopathic Parkinson's Disease","enrollment":25},{"nctId":"NCT00947037","phase":"PHASE2","title":"Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study","status":"WITHDRAWN","sponsor":"Intec Pharma Ltd.","startDate":"2012-08","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT01515410","phase":"PHASE2","title":"Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations","status":"COMPLETED","sponsor":"Depomed","startDate":"2012-01","conditions":"Parkinson's Disease, Motor Fluctuations","enrollment":34},{"nctId":"NCT01351168","phase":"PHASE2","title":"Use of Zolpidem in Parkinson's Disease","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"","conditions":"Parkinson's Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Levodopa/Carbidopa (LD/CD)","genericName":"Levodopa/Carbidopa (LD/CD)","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levodopa/Carbidopa (LD/CD) is a medication used to treat Parkinson's Disease, specifically motor fluctuations in advanced cases. It works by inhibiting the enzyme aromatic-L-amino-acid decarboxylase, which is involved in the breakdown of levodopa.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}